VIDEO: Genetic mutations may affect outcome of AML in favorable-risk disease
In this video, Alexander Edward Perl, MD, MS, discusses a study that showed patients with acute myeloid leukemia with genetic predictors of favorable-risk disease might still have poorer outcomes because of certain genetic mutations.
Perl, associate professor of medicine in the department of hematology at the Hospital of the University of Pennsylvania, said the study, which was presented at the virtual Society of Hematologic Oncology Annual Meeting, evaluated patients with favorable-risk disease, as determined by the European LeukemiaNet (ELN) risk stratification system, some of whom also had genetic mutations known to be associated with secondary AML.
“Patients who had these mutations had really dismal outcomes as compared with patients who did not have those mutations, so it’s important when looking at patients with the ELN classification to recognize that it can be a little more complicated than the ELN classification has made in using a limited number of mutations to guide prognostication for patients,” Perl told Healio.
Collapse
Chan O, et al. Mutations Highly Specific for Secondary AML are Associated with Poor Outcomes Even in Patients with NPM1 Mutated ELN Favorable Risk AML. Presented at: Society of Hematologic Oncology Annual Meeting; Sept. 8-11, 2021 (virtual meeting).